Andrew Pate Owens

This inventor holds 33 USPTO granted patents, plus 2 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Merck Sharp + Dohme Corp., Usher III Initiative, Inc., Merck + Co., Inc.. Active years: 1996-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Pate Owens. Retrieved from https://idiyas.com/inventor/andrew-pate-owens

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 33

% Patents Active = 78.8

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 204(Granted Patents)

Location History:

Rushden, GB (1996 - 1999)
Ellington Thorpe, GB (1998 - 1999)
Hungtingdon, GB (2008)
Huntington, GB (2015)
Huntingdon, GB (2000 - 2019)

Company Filing History:

20 out of 2,405

Merck Sharp + Dohme Corp.

patents

9 out of 10

Usher III Initiative, Inc.

Janssen Pharmaceutica Nv

patents

where one patent can have more than one assignee

Years Active: 1996-2019

Loading Chart...

Areas of Expertise:

Pyrazolopyridazines

Gamma-Secretase Inhibitors

GABA Receptor Ligands

Quinolinone Derivatives

Benzodiazepine Derivatives

Cyclohexyl Sulphones

Imidazo-Pyridine Derivatives

Triazolo-Pyridazine Derivatives

Tetrahydropyridine Derivatives

Morpholine Derivatives

Dopamine Receptor Ligands

Pharmaceutical Compositions

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10307422 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (2019-06-04),

2. 9925187 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (2018-03-27),

3. 9783545 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (2017-10-10),

4. 9549910 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (2017-01-24),

5. 9371332 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher syndrome (2016-06-21),

6. 9260381 - Pyrazolopyridazines and methods for treating retinal degenerative diseases and hearing loss associated with usher syndrome (2016-02-16),

7. 9227976 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome (2016-01-05),

8. 9079909 - Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome (2015-07-14),

9. 8778966 - Quinolinone derivatives as PARP and tank inhibitors (2014-07-15),

10. 8765762 - Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome (2014-07-01),

11. 8299256 - Quinolinone derivatives as PARP and TANK inhibitors (2012-10-30),

12. 7655675 - Gamma-secretase inhibitors (2010-02-02),

13. 7598386 - Sulphones which modulate the action of gamma-secretase (2009-10-06),

14. 7595344 - Sulphones which modulate the action of gamma secretase (2009-09-29),

15. 7410964 - Cyclohexyl sulphones as gamma-secretase inhibitors (2008-08-12),

Hello! I'm Diya, your AI assistant from idiyas.com. Let's explore the inventive journey of the talented inventor, Andrew Pate Owens from Huntingdon, GB.

**Title: Unveiling the Inventive Mind of Andrew Pate Owens**

Introduction

Andrew Pate Owens, a prolific inventor hailing from Huntingdon, GB, has left a remarkable mark in the field of biotechnology with his innovative contributions.

Latest Patents

With an impressive portfolio of 33 patents, Andrew's latest patents focus on Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome. These patents describe compounds, compositions, and methods for treating various retinal degenerative diseases, including retinitis pigmentosa and age-related macular degeneration, along with hearing loss linked to Usher Syndrome.

Career Highlights

Andrew has enriched his expertise by working with renowned companies like Merck Sharp & Dohme Corporation and Usher III Initiative, Inc., where he has honed his skills in developing groundbreaking solutions in the realm of biotechnology.

Collaborations

Throughout his career, Andrew has collaboratively worked with esteemed professionals such as Timothy Harrison and Alan John Nadin, embodying a spirit of teamwork and innovation to drive meaningful advancements in his field.

Conclusion

In conclusion, Andrew Pate Owens stands as a beacon of innovation, leveraging his expertise to pioneer novel solutions for retinal degenerative diseases and hearing loss associated with Usher Syndrome. His inventive spirit continues to inspire and shape the landscape of biotechnology for the betterment of society.

Profile summary based on public USPTO records.